On-demand webinar thumbnail with a blurred gold and blue particle background

Identifying the Best Populations to Target, De-Risking Discovery and Early-Stage Development

1 minute read

Published: June 3rd, 2026

About This Webinar

In this session, we explore real-world use cases where AI and LLMs (Large Language Models) have been applied to explore large data sources such as omics, literature, and real-world data (RWD). We explore how AI can help identify optimal target populations, endpoints, and even support drug repurposing.

Speaker:

Billy Amzal, Ph.D.
Head of Strategic Consulting, Phastar

Key Takeaways:

  • How AI helps explore large datasets for drug development
  • De-risking clinical research using AI for precision care
  • Real-world examples of AI transforming early-stage development
Complete the form below to access the recording and slides:

Related articles

Regulatory Expectations: Bayesian Guidance from the FDA, CDE, and EMA

Regulatory Expectations: Bayesian Guidance from the FDA, CDE, and EMA

July 21st, 2026 1 minute read

Bayesian methods are increasingly being considered to support dose optimization, extrapolation, and adaptive designs ...

AI for Clinical Research Series – Prediction

AI for Clinical Research Series – Prediction

June 26th, 2026 1 minute read

Augmenting Clinical Trials with Synthetic or Simulated Patients, Projecting Long-Term Benefit-Risk, and Developing Re...

A Systematic Review into the Use of Bayesian Methods in Clinical Trials

A Systematic Review into the Use of Bayesian Methods in Clinical Trials

June 25th, 2026 2 minute read

Bayesian methods continue to gain momentum as an alternative approach to traditional clinical trial design, yet many ...